NOTES
TO CONDENSED CONSOLIDATED FINANCIAL STATEMENTS
(Unaudited)
Three
Months and Six Months Ended June 30, 2019 and 2018
1.
Organization and Basis of Presentation
Organization
RespireRx
Pharmaceuticals Inc. (“RespireRx”) was formed in 1987 under the name Cortex Pharmaceuticals, Inc. to engage in the
discovery, development and commercialization of innovative pharmaceuticals for the treatment of neurological and psychiatric disorders.
On December 16, 2015, RespireRx filed a Certificate of Amendment to its Second Restated Certificate of Incorporation with the
Secretary of State of the State of Delaware to amend its Second Restated Certificate of Incorporation to change its name from
Cortex Pharmaceuticals, Inc. to RespireRx Pharmaceuticals Inc. While developing potential applications for respiratory disorders,
RespireRx has retained and expanded its ampakine intellectual property and data with respect to neurological and psychiatric disorders
and is considering developing certain potential products in this platform, pending additional financing and/or strategic relationships.
In
August 2012, RespireRx acquired Pier Pharmaceuticals, Inc. (“Pier”), which is now its wholly-owned subsidiary.
Basis
of Presentation
The
condensed consolidated financial statements are of RespireRx and its wholly-owned subsidiary, Pier (collectively referred to herein
as the “Company,” “we” or “our,” unless the context indicates otherwise). The condensed consolidated
financial statements of the Company at June 30, 2019 and for the six months and three months ended June 30, 2019 and 2018, are
unaudited. In the opinion of management, all adjustments (including normal recurring adjustments) have been made that are necessary
to present fairly the condensed consolidated financial position of the Company as of June 30, 2019 and the results of its condensed
consolidated operations for the six months and three months ended June 30, 2019 and 2018. Condensed consolidated operating results
for the interim periods presented are not necessarily indicative of the results to be expected for a full fiscal year. The consolidated
balance sheet at December 31, 2018 has been derived from the Company’s audited consolidated financial statements at such
date.
The
condensed consolidated financial statements and related notes have been prepared pursuant to the rules and regulations of the
Securities and Exchange Commission (the “SEC”). Accordingly, certain information and note disclosures normally included
in financial statements prepared in accordance with generally accepted accounting principles have been omitted pursuant to such
rules and regulations. These condensed consolidated financial statements should be read in conjunction with the consolidated financial
statements and other information included in the Company’s Annual Report on Form 10-K for the fiscal year ended December
31, 2018, as filed with the SEC.
2.
Business
The
mission of the Company is to develop innovative and revolutionary treatments to combat diseases caused by disruption of neuronal
signaling. We are developing treatment options that address conditions that affect millions of people, but for which there are
few or poor treatment options, including obstructive sleep apnea (“OSA”), attention deficit hyperactivity disorder
(“ADHD”) and recovery from spinal cord injury (“SCI”), as well as certain neurological orphan diseases
such as Fragile X Syndrome. RespireRx is developing a pipeline of new drug products based on our broad patent portfolios for two
drug platforms: cannabinoids, including dronabinol (“∆9-THC”), and the ampakines, proprietary compounds that
positively modulate AMPA-type glutamate receptors to promote neuronal function.
RespireRx
is developing a number of potential products. From the cannabinoid platform, two Phase 2 clinical trials have been completed demonstrating
the ability of dronabinol to significantly reduce the symptoms of OSA, which management believes is potentially a multi-billion-dollar
market. Subject to raising sufficient financing (of which no assurance can be provided), we believe that we have put most of the
necessary pieces into place to rapidly initiate a Phase 3 clinical trial program. By way of definition, when a new drug is allowed
by the United States Food and Drug Administration (“FDA”) to be tested in humans, Phase 1 clinical trials are conducted
in healthy people to determine safety and pharmacokinetics. If successful, Phase 2 clinical trials are conducted in patients to
determine safety and preliminary efficacy. Phase 3 trials, large scale studies to determine efficacy and safety, are the final
step prior to seeking FDA approval to market a drug.
From
our ampakine platform, our lead clinical compounds, CX717 and CX1739, have successfully completed multiple Phase 1 safety trials.
Both compounds have also completed Phase 2 efficacy trials demonstrating target engagement, by antagonizing the ability of opioids
to induce respiratory depression. CX717 has completed a Phase 2 trial demonstrating the ability to significantly reduce the symptoms
of adult ADHD. In an early Phase 2 study, CX1739 improved breathing in patients with central sleep apnea. Preclinical studies
have highlighted the potential ability of these ampakines to improve motor function in animals with spinal injury. Subject to
raising sufficient financing (of which no assurance can be provided), we believe that we will be able to rapidly initiate a human
Phase 2 study with CX1739 and/or CX717 in patients with spinal cord injury and a human Phase 2B study in patients with ADHD with
either CX717 or CX1739.
Going
Concern
The
Company’s condensed consolidated financial statements have been presented on the basis that it is a going concern, which
contemplates the realization of assets and satisfaction of liabilities in the normal course of business. The Company has incurred
net losses of $1,017,545 and $477,213 for the six months and three-months ended June 30, 2019, respectively and $2,591,790
for the fiscal year ended December 31, 2018, and negative operating cash flows of $266,278 for the six months ended June 30, 2019
and $427,368 for the fiscal year ended December 31, 2018. The Company had only $6 of cash at June 30, 2019 and also had a stockholders’
deficiency of $6,617,038 at June 30, 2019 and expects to continue to incur net losses and negative operating cash flows for at
least the next few years. As a result, management has concluded that there is substantial doubt about the Company’s ability
to continue as a going concern, and the Company’s independent registered public accounting firm, in its report on the Company’s
consolidated financial statements for the year ended December 31, 2018, expressed substantial doubt about the Company’s
ability to continue as a going concern.
The
Company is currently, and has for some time, been in significant financial distress. It has extremely limited cash resources and
current assets and has no ongoing source of sustainable revenue. Management is continuing to address various aspects of the Company’s
operations and obligations, including, without limitation, debt obligations, financing requirements, intellectual property, licensing
agreements, legal and patent matters and regulatory compliance, and has taken steps to continue to raise new debt and equity capital
to fund the Company’s business activities from both related and unrelated parties.
The
Company is continuing its efforts to raise additional capital in order to be able to pay its liabilities and fund its
business activities on a going forward basis, including the pursuit of the Company’s planned research and development
activities. The Company regularly evaluates various measures to satisfy the Company’s liquidity needs, including
development and other agreements with collaborative partners and, when necessary, seeking to exchange or restructure the
Company’s outstanding securities. The Company is evaluating certain changes to its operations and structure to
facilitate raising capital from sources that may be interested in financing only discrete aspects of the Company’s
development programs. Such changes could include a significant reorganization, which may include the formation of one or more
subsidiaries into which one or more programs may be contributed. As a result of the Company’s current financial
situation, the Company has experienced very limited access to external sources of debt and equity financing and the cost
of such capital, both in terms of rates and other conditions, has been high. Accordingly, there can be no assurances that
the Company will be able to secure additional financing in the amounts necessary to fully fund its operating and debt service
requirements. If the Company is unable to access sufficient cash resources, the Company may be forced to discontinue its
operations entirely and liquidate.
3.
Summary of Significant Accounting Policies
Principles
of Consolidation
The
accompanying condensed consolidated financial statements are prepared in accordance with United States generally accepted accounting
principles (“GAAP”) and include the financial statements of RespireRx and its wholly-owned subsidiary, Pier. Intercompany
balances and transactions have been eliminated in consolidation.
Use
of Estimates
The
preparation of financial statements in conformity with GAAP requires management to make estimates and assumptions. These estimates
and assumptions affect the reported amounts of assets and liabilities, disclosure of contingent assets and liabilities at the
date of the financial statements and the reported amounts of revenues and expenses during the reporting period. Significant estimates
include, among other things, accounting for potential liabilities, and the assumptions used in valuing stock-based compensation
issued for services. Actual amounts may differ from those estimates.
Concentration
of Risk
Financial
instruments that potentially subject the Company to concentrations of credit risk consist primarily of cash and cash equivalents.
The Company limits its exposure to credit risk by investing its cash with high credit quality financial institutions.
The
Company’s research and development efforts and potential products rely on licenses from research institutions and if the
Company loses access to these technologies or applications, its business could be substantially impaired.
Cash
Equivalents
The
Company considers all highly liquid short-term investments with maturities of less than three-months when acquired to be cash
equivalents.
Fair
Value of Financial Instruments
The
authoritative guidance with respect to fair value of financial instruments established a fair value hierarchy that prioritizes
the inputs to valuation techniques used to measure fair value into three levels and requires that assets and liabilities carried
at fair value be classified and disclosed in one of three categories, as presented below. Disclosure as to transfers into and
out of Levels 1 and 2, and activity in Level 3 fair value measurements, is also required.
Level
1. Observable inputs such as quoted prices in active markets for an identical asset or liability that the Company has the ability
to access as of the measurement date. Financial assets and liabilities utilizing Level 1 inputs include active-exchange traded
securities and exchange-based derivatives.
Level
2. Inputs, other than quoted prices included within Level 1, which are directly observable for the asset or liability or indirectly
observable through corroboration with observable market data. Financial assets and liabilities utilizing Level 2 inputs include
fixed income securities, non-exchange based derivatives, mutual funds, and fair-value hedges.
Level
3. Unobservable inputs in which there is little or no market data for the asset or liability which requires the reporting entity
to develop its own assumptions. Financial assets and liabilities utilizing Level 3 inputs include infrequently-traded, non- exchange-based
derivatives and commingled investment funds, and are measured using present value pricing models.
The
Company determines the level in the fair value hierarchy within which each fair value measurement falls in its entirety, based
on the lowest level input that is significant to the fair value measurement in its entirety. In determining the appropriate levels,
the Company performs an analysis of the assets and liabilities at each reporting period end.
The
carrying amounts of financial instruments (consisting of cash, cash equivalents, advances on research grants and accounts payable
and accrued expenses) are considered by the Company to be representative of the respective fair values of these instruments due
to the short-term nature of those instruments. With respect to the note payable to SY Corporation and the convertible notes payable,
management does not believe that the credit markets have materially changed for these types of borrowings since the original borrowing
date. The Company considers the carrying amounts of the notes payable to officers, inclusive of accrued interest, to be representative
of the respective fair values of such instruments due to the short-term nature of those instruments and their terms.
Convertible
Notes Payable
Convertible
notes are evaluated to determine if they should be recorded at amortized cost. To the extent that there are associated warrants
or a beneficial conversion feature, the convertible notes and warrants are evaluated to determine if there are embedded derivatives
to be identified, bifurcated and valued at fair value in connection with and at the time of such financing. The value of debt
discounts such as warrants, beneficial conversion features and original issue discounts are recorded as contra debt and amortized
into interest expense over the life of the notes.
Extinguishment
of Debt
The
Company accounts for the extinguishment of debt in accordance with GAAP by comparing the carrying value of the debt to the fair
value of consideration paid or assets given up and recognizing a loss or gain in the condensed consolidated statement of operations
in the amount of the difference in the period in which such transaction occurs.
Equipment
Equipment
is recorded at cost and depreciated on a straight-line basis over their estimated useful lives, which range from three to five
years. All equipment was fully depreciated as of June 30, 2019.
Prepaid
Insurance
Long-term
prepaid insurance represents the premium paid in March 2014 for directors’ and officers’ insurance tail coverage,
which is being amortized on a straight-line basis over the policy period of six years. The amount amortizable in the ensuing twelve-
month period is recorded as a current asset in the Company’s condensed consolidated balance sheet at each reporting date.
As of June 30, 2019, all such prepaid amounts have been reclassified as current since the policy will expire within one year.
Impairment
of Long-Lived Assets
The
Company reviews its long-lived assets, including long-term prepaid insurance, for impairment whenever events or changes in circumstances
indicate that the total amount of an asset may not be recoverable, but at least annually. An impairment loss is recognized when
estimated future cash flows expected to result from the use of the asset and its eventual disposition is less than the asset’s
carrying amount. The Company has not deemed any long-lived assets as impaired at June 30, 2019.
Stock-Based
Awards
The
Company periodically issues common stock and stock options to officers, directors, outside consultants and vendors for services
rendered. Such issuances vest and expire according to terms established at the issuance date of each grant.
The
Company accounts for stock-based payments to officers, directors, outside consultants and vendors by measuring the cost of services
received in exchange for equity awards based on the grant date fair value of the awards, with the cost recognized as compensation
expense on the straight-line basis in the Company’s consolidated financial statements over the vesting period of the awards.
The
fair value of stock options granted as stock-based payments is determined utilizing the Black-Scholes option-pricing model, and
is affected by several variables, the most significant of which are the life of the equity award, the exercise price of the stock
option as compared to the fair market value of the common stock on the grant date, and the estimated volatility of the common
stock over the term of the equity award. Estimated volatility is based on the historical volatility of the Company’s common
stock. The risk- free interest rate is based on the U.S. Treasury yield curve in effect at the time of grant. The fair market
value of common stock is determined by reference to the quoted market price of the Company’s common stock.
There
were no stock or stock option grants during the six months ended June 30, 2019.
For
stock options requiring an assessment of value during the six months ended June 30, 2018, the fair value of each stock option
award was estimated using the Black-Scholes option-pricing model using the following assumptions:
Risk-free interest rate
|
|
|
2.56
|
%
|
Expected dividend yield
|
|
|
0
|
%
|
Expected volatility
|
|
|
185.41
|
%
|
Expected life
|
|
|
4.7
|
|
The
Company recognizes the fair value of stock-based payments in general and administrative costs and in research and development
costs, as appropriate, in the Company’s condensed consolidated statements of operations. The Company issues new shares of
common stock to satisfy stock option and warrant exercises. There were no stock options exercised during the six months ended
June 30, 2019 and 2018.
Income
Taxes
The
Company accounts for income taxes under an asset and liability approach for financial accounting and reporting for income taxes.
Accordingly, the Company recognizes deferred tax assets and liabilities for the expected impact of differences between the financial
statements and the tax basis of assets and liabilities.
The
Company records a valuation allowance to reduce its deferred tax assets to the amount that is more likely than not to be realized.
In the event the Company was to determine that it would be able to realize its deferred tax assets in the future in excess of
its recorded amount, an adjustment to the deferred tax assets would be credited to operations in the period such determination
was made. Likewise, should the Company determine that it would not be able to realize all or part of its deferred tax assets in
the future, an adjustment to the deferred tax assets would be charged to operations in the period such determination was made.
Pursuant
to Internal Revenue Code Sections 382 and 383, use of the Company’s net operating loss and credit carryforwards may be limited
if a cumulative change in ownership of more than 50% occurs within any three-year period since the last ownership change. The
Company may have had a change in control under these Sections. However, the Company does not anticipate performing a complete
analysis of the limitation on the annual use of the net operating loss and tax credit carryforwards until the time that it anticipates
it will be able to utilize these tax attributes.
As
of June 30, 2019, the Company did not have any unrecognized tax benefits related to various federal and state income tax matters
and does not anticipate any material amount of unrecognized tax benefits within the next 12 months.
The
Company is subject to U.S. federal income taxes and income taxes of various state tax jurisdictions. As the Company’s net
operating losses have yet to be utilized, all previous tax years remain open to examination by Federal authorities and other jurisdictions
in which the Company currently operates or has operated in the past.
The
Company accounts for uncertainties in income tax law under a comprehensive model for the financial statement recognition, measurement,
presentation and disclosure of uncertain tax positions taken or expected to be taken in income tax returns as prescribed by GAAP.
The tax effects of a position are recognized only if it is “more-likely-than-not” to be sustained by the taxing authority
as of the reporting date. If the tax position is not considered “more-likely-than-not” to be sustained, then no benefits
of the position are recognized. As of June 30, 2019, the Company had not recorded any liability for uncertain tax positions. In
subsequent periods, any interest and penalties related to uncertain tax positions will be recognized as a component of income
tax expense.
Foreign
Currency Transactions
The
note payable to SY Corporation, which is denominated in a foreign currency (the South Korean Won), is translated into the Company’s
functional currency (the United States Dollar) at the exchange rate on the balance sheet date. The foreign currency exchange gain
or loss resulting from translation is recognized in the related condensed consolidated statements of operations.
Research
and Development
Research
and development costs include compensation paid to management directing the Company’s research and development activities,
and fees paid to consultants and outside service providers and organizations (including research institutes at universities),
and other expenses relating to the acquisition, design, development and clinical testing of the Company’s treatments and
product candidates.
Research
and development costs incurred by the Company under research grants are expensed as incurred over the life of the underlying contracts,
unless the terms of the contract indicate that a different expensing schedule is more appropriate.
The
Company reviews the status of its research and development contracts on a quarterly basis.
On
May 6, 2016, the Company made an advance payment to Duke University with respect to the Phase 2A clinical trial of CX1739. At
June 30, 2019, an asset balance of $48,912 remained from the advance payment.
License
Agreements
Obligations
incurred with respect to mandatory payments provided for in license agreements are recognized ratably over the appropriate period,
as specified in the underlying license agreement, and are recorded as liabilities in the Company’s condensed consolidated
balance sheet, with a corresponding charge to research and development costs in the Company’s condensed consolidated statement
of operations. Obligations incurred with respect to milestone payments provided for in license agreements are recognized when
it is probable that such milestone will be reached and are recorded as liabilities in the Company’s condensed consolidated
balance sheet, with a corresponding charge to research and development costs in the Company’s condensed consolidated statement
of operations. Payments of such liabilities are made in the ordinary course of business.
Patent
Costs
Due
to the significant uncertainty associated with the successful development of one or more commercially viable products based on
the Company’s research efforts and any related patent applications, all patent costs, including patent-related legal and
filing fees, are expensed as incurred and recorded as general and administrative expenses.
Earnings
per Share
The
Company’s computation of earnings per share (“EPS”) includes basic and diluted EPS. Basic EPS is measured as
the income (loss) attributable to common stockholders divided by the weighted average common shares outstanding for the period.
Diluted EPS is similar to basic EPS but presents the dilutive effect on a per share basis of potential common shares (e.g., warrants
and options) as if they had been converted at the beginning of the periods presented, or issuance date, if later. Potential common
shares that have an anti-dilutive effect (i.e., those that increase income per share or decrease loss per share) are excluded
from the calculation of diluted EPS.
Net
loss attributable to common stockholders consists of net loss, as adjusted for actual and deemed preferred stock dividends declared,
amortized or accumulated.
Loss
per common share is computed by dividing net loss by the weighted average number of shares of common stock outstanding during
the respective periods. Basic and diluted loss per common share is the same for all periods presented because all warrants and
stock options outstanding are anti-dilutive.
At
June 30, 2019 and 2018, the Company excluded the outstanding securities summarized below, which entitle the holders thereof to
acquire shares of common stock, from its calculation of earnings per share, as their effect would have been anti-dilutive.
|
|
June 30,
|
|
|
|
2019
|
|
|
2018
|
|
Series B convertible preferred stock
|
|
|
11
|
|
|
|
11
|
|
Convertible notes payable
|
|
|
564,797
|
|
|
|
29,957
|
|
Common stock warrants
|
|
|
1,876,198
|
|
|
|
1,464,415
|
|
Common stock options
|
|
|
4,333,763
|
|
|
|
4,012,929
|
|
Total
|
|
|
6,774,769
|
|
|
|
5,507,312
|
|
Reclassifications
Certain
comparative figures in 2018 have been reclassified to conform to the current six month and three month presentation. These reclassifications
were immaterial, both individually and in the aggregate.
Recent
Accounting Pronouncements
In
June 2018, the FASB issued Accounting Standards Update No. 2018-07 (“ASU 2018-07”),
Compensation-Stock Compensation
(Topic 718)—Improvements to Nonemployee Share-Based Payment Accounting.
ASU 2018-07 are amendments to Topic 718 that
become effective for public entities like the Company for fiscal years beginning after December 15, 2018, including interim periods
within that fiscal year. This update applies to nonemployee share-based awards within the scope of Topic 718. Consistent with
the accounting requirement for employee share-based payment awards, nonemployee share-based payment awards are measured at grant-date
fair value of the equity instruments that an entity is obligated to issue when the good has been delivered or the service has
been rendered and any other conditions necessary to earn the right to benefit from the instruments have been satisfied. Equity-
classified nonemployee share- based payment awards are measured at the grant date. The definition of the term grant date has been
amended to generally state the date at which a grantor and a grantee reach a mutual understanding of the key terms and conditions
of a share- based payment award. An entity considers the probability of satisfying performance conditions when nonemployee share-based
payment awards contain such conditions. This is consistent with the treatment for employee-based awards. Generally, the classification
of equity- classified nonemployee share-based payment awards will continue to be subject to the requirements of Topic 718 unless
modified after the good has been delivered, the service has been rendered, any other conditions necessary to earn the right to
benefit from the instruments have been satisfied, and the nonemployee is no longer providing goods or services. This eliminates
the requirement to reassess classification of such awards upon vesting. This standard will change the valuation of applicable
awards granted in subsequent periods.
In
July 2017, the FASB issued Accounting Standards Update No. 2017-11 (“ASU 2017-11”),
Earnings Per Share (Topic 260):
Distinguishing Liabilities from Equity (Topic 480): Derivatives and Hedging (Topic 815)
. The relevant section for the Company
is Topic 815 where it pertains to accounting for certain financial instruments with down round features. Until the issuance of
this ASU, financial instruments with down round features required fair value measurement and subsequent changes in fair value
were recognized in earnings. As a result of the ASU, financial instruments with down round features are no longer treated as a
derivative liability measured at fair value. Instead, when the down round feature is triggered, the effect is treated as a dividend
and as a reduction of income available to common shareholders in basic earnings per share. For public entities, the ASU is effective
for fiscal years beginning after December 15, 2018. Early adoption is permitted including adoption in an interim period. The adoption
of ASU 2017- 11 did not have any impact on the Company’s financial statement presentation or disclosures.
4.
Notes Payable
Convertible
Notes Payable
On May 17, 2019, the
Company issued a master convertible note (“May 2019 Convertible Note”) issuable in tranches, bearing interest at 10%
per year, bearing a maximum maturity amount of $150,000. The first tranche has a maturity amount of $50,000 and matures on the
one year anniversary of the tranche which is May 17, 2020. There was a stated original issue discount of $5,000 and the Company
incurred debt issuance costs of $2,000 for lender legal fees. Therefore, the net proceeds to the Company was $43,000. Subject
to certain limitations and adjustments as described in the May 2019 Convertible Note, the holder may convert from the date of
issuance to the maturity date, part or all of the May 2019 Convertible Note, inclusive of accrued interest, into the Company’s
Common Stock at a variable conversion price that is the lesser of (i) lowest trading price as such term is defined in the May
2019 Convertible Note (the lowest closing bid price) in the twenty five day trading period prior to the date of the May 2019 Convertible
Note (which price is now fixed at $0.25, the closing bid price on May 16, 2019), or (ii) the variable conversion price (as defined
in the May 2019 Convertible Note) which is 61% of the market price (as defined in the May 2019 Convertible Note). The market price
is the lowest trading price (closing bid) in the twenty five day trading day period up to the day prior to the conversion. If
at any time while the Note is outstanding, the conversion price is equal to or lower than $0.35, then an additional eleven percent
(11%) discount is to be factored into the conversion price until the May 2019 Convertible Note is no longer outstanding (resulting
in a discount rate of 50% assuming no other adjustments are triggered). Both the lowest trading price on the date of inception
of the May 2019 Convertible Note ($0.25) and the lowest market price were both below $0.35, the effective conversion rate on the
inception date was $0.125. Therefore, on the inception date, the first tranche would convert into 400,000 shares of the Company’s
Common Stock, par value $0.001. The Company evaluated all of the terms of the May 2019 Convertible Note and determined that, in
accordance with Accounting Standard Codification (ASC) 815, there were no derivatives to be bifurcated or separately valued. However,
there were four features of the May 2019 Convertible Note, the related securities purchase agreement and the warrant that was
issued in connection therewith that required valuation. There were: (i) the original issue discount of $5,000, (ii) the debt issuance
costs of $2,000, (iii) the beneficial conversion feature and (iv) the value of the warrant. The Company amortized (i) and (ii)
above on a straight-line basis over the life of the tranche. The Company evaluated (iii) the intrinsic value of the beneficial
conversion feature for a calculated value of $286,000 (($0.84 closing price minus $0.125 conversion price) x 400,000 shares).
The Company calculated the warrant value using the Black-Scholes valuation method, utilizing the following assumptions: (a) exercise
price of $1.18 per share, (b) stock price $0.84, (c) three year life (d) three year risk free rate of 2.15% and (e) volatility
of 210.19% and determined that the value of one warrant was $0.774 and the total warrant value was $32,796 for the warrant exercisable
into 42,373 shares of the Company’s Common Stock, par value $0.001. The amount to be recorded initially as the amount of
the May 2019 Convertible Note was then calculated by determining the relative values as percentages of the maturity amount
of the May 2019 Convertible Note ($50,000), the beneficial conversion feature ($286,000) and the warrant ($32,796). The respective
percentages were 13.56%, 77.55 and 8.89%. The original issue discount, debt issuance costs, the intrinsic value of the beneficial
conversion feature and proceeds allocated to the value of the warrant are being amortized to interest expense on a straight-line
basis over the life the May 2019 Convertible Note.
The
May 2019 Convertible Note consists of the following at June 30, 2019.
Principal amount of note payable
|
|
$
|
50,000
|
|
Debt issuance costs, net of amortization of $247
|
|
|
(1,753
|
)
|
Original issue discount, net of amortization of $616
|
|
|
(4,384
|
)
|
Discount associated with beneficial conversion feature,
net of amortization of $5,001
|
|
|
(33,773
|
)
|
Discount associated with warrant, net of amortization
of $548
|
|
|
(3,898
|
)
|
Accrued coupon interest
|
|
|
616
|
|
|
|
$
|
6,808
|
|
On April 24, 2019, the
Company issued a convertible note (“April 2019 Convertible Note”) bearing interest at 10% per year. The maturity amount
is $58,500 and matures on the one year anniversary which is April 24, 2020. The Company incurred debt issuance costs of $3,500
for lender legal and due diligence fees. There was no stated original issue discount and no warrants were issued in connection
with the April 2019 Convertible Note. The net proceeds to the Company was $50,000. Subject to certain limitations and adjustments
as described in the April 2019 Convertible Note, the holder may, from the date that is one hundred eighty (180) days after
the issuance to the maturity date, convert part or all of the April 2019 Convertible Note, inclusive of accrued interest, into
the Company’s Common Stock at a variable conversion price that is 61% of the market price as defined in the April 2019 Convertible
Note. The market price is the lowest trading price, which in turn is the lowest closing bid price in the twenty (20) trading days
prior to conversion. The lowest closing bid price in the twenty (20) day period prior to inception was $0.65 which would calculate
to a $0.3964 conversion price and further calculate to 147,541 conversion shares to be issued. The Company evaluated all of the
terms of the April 2019 Convertible Note and determined that, in accordance with ASC 815, there were no derivatives to be bifurcated
or separately valued. However, there were two features of the April 2019 Convertible Note and the related securities purchase
agreement that required valuation. There were: (i) the debt issuance costs of $3,500, and (ii) the intrinsic value of the beneficial
conversion feature. The Company amortized (i) on a straight-line basis over the life of the April 2019 Convertible Note. The Company
evaluated (ii) as the closing price on the inception date minus the conversion price multiplied by the number of conversion shares
and determined that the beneficial conversion feature had an intrinsic value of $44,950 (($0.701 closing price minus $0.3964 conversion
price) x 147,541 shares). The debt issuance costs and the amount recorded as the intrinsic value of the beneficial conversion
feature are each being amortized to interest expense on a straight-line basis over the life the April 2019 Convertible Note.
The
April 2019 Convertible Note consists of the following at June 30, 2019.
Principal amount of note payable
|
|
$
|
58,500
|
|
Capitalized note costs, net of amortization of $652
|
|
|
(2,848
|
)
|
Discount associated with beneficial conversion feature, net of amortization
of $8,374
|
|
|
(36,575
|
)
|
Accrued coupon interest
|
|
|
1,089
|
|
|
|
$
|
20,166
|
|
On
January 2, 2019, February 27, 2019, March 6, 2019 and March 14, 2019, the Company issued convertible notes (“2019 Convertible
Notes”) bearing interest at 10% per year. The January 2, 2019 Convertible Note matured on February 28, 2019 with a face
amount of $10,000. The February 27, 2019, March 6, 2019 and March 14, 2019, 2019 Convertible Notes matured on April 30, 2019 with
an aggregate face amount of $100,000. Investors also received an aggregate of 110,000 common stock purchase warrants. The warrants
were valued using the Black Scholes option pricing model calculated on the date of each grant and had an aggregate value of $78,780.
Total value received by the investors was $188,780, the sum of the face value of the convertible note and the value of the warrant.
Therefore, the Company recorded an initial original issue discount of $45,812 and an initial value of the convertible notes of
$64,188 using the relative fair value method. An additional $3,842 and $1,061 of interest expense was recorded based upon the
10% annual rate for the six months and three months ended June 30, 2019, respectively. The 2019 Convertible Note that matured
on February 28, 2019 was not paid and remains outstanding and continues to accrue interest. The 2019 Convertible Notes that matured
on April 30, 2019 were not paid and remain outstanding and continue to accrue interest. Although the 2019 Convertible
Notes are in default, the Company has not received any notices of default from any of the note holders. The 2019 Convertible Notes
have no reset rights or other protections based on subsequent equity transactions, equity-linked transactions or other events
other than the right, but not the obligation, for each investor to convert or exchange his or her 2019 Convertible Note, but not
the warrant, into the next exempt private securities offering. The May 2019 Convertible Note and April 2019 Convertible Note,
which the Company does not consider to have arisen from an offering, may be interpreted in such a way that the 2019 Convertible
Note Holders have the right to convert or exchange. However, no holders of such notes have requested a conversion or exchange.
The Company does not believe that an offering occurred as of June 30, 2019 or as of the date of the issuance of these financial
statements. Therefore, the number of shares of common stock (or preferred stock) into which the 2019 Convertible Notes may convert
is not determinable and the Company has not accounted for any additional consideration. The warrants to purchase 110,000 shares
of common stock issued in connection with the sale of the 2019 Convertible Notes are exercisable at a fixed price of $1.50 per
share of common stock, provide no right to receive a cash payment, and included no reset rights or other protections based on
subsequent equity transactions, equity-linked transactions or other events. The Company determined that there were no embedded
derivatives to be identified, bifurcated and valued in connection with this financing.
During
December 2018, convertible notes (“2018 Convertible Notes”) bearing interest at 10% per year and maturing on February
28, 2019 and warrants were sold to investors with an aggregate face amount of $80,000. Investors also received 80,000 common stock
purchase warrants. The warrants were valued using the Black Scholes option pricing model calculated on the date of each grant
and had an aggregate value of $68,025. Total value received by the investors was $148,025, the sum of the face value of the convertible
note and the value of the warrant. Therefore, the Company recorded an initial original issue discount of $36,347 and an initial
value of the convertible notes of $43,653 using the relative fair value method. An additional $4,022 and $2,000 of interest expense
was recorded based upon the 10% annual rate for the six months and three months ended June 30, 2019. The 2018 Convertible Notes
matured on February 28, 2019, were not paid, remain outstanding and continue to accrue interest. Although the 2018 Convertible
Notes are in default, the Company has not received any notices of default from any of the note holders. The 2018 Convertible Notes
have no reset rights or other protections based on subsequent equity transactions, equity-linked transactions or other events
other than the right, but not the obligation for each investor to convert or exchange his or her 2018 Convertible Note, but not
the warrant, into the next exempt private securities offering. The May 2019 Convertible Note and April 2019 Convertible Note,
which the Company does not consider to have arisen from an offering, may be interpreted in such a way that the 2019 Convertible
Note Holders have the right to convert or exchange. However, no holders of such notes have requested a conversion or exchange.
The Company does not believe that an offering occurred as of June 30, 2019 or as of the date of the issuance of these
financial statements. Therefore, the number of shares of common stock (or preferred stock) into which the 2018 Convertible Notes
may convert is not determinable and the Company has not accounted for any additional consideration. The warrants to purchase 80,000
shares of common stock issued in connection with the sale of the 2018 Convertible Notes are exercisable at a fixed price of $1.50
per share of common stock, provide no right to receive a cash payment, and included no reset rights or other protections based
on subsequent equity transactions, equity-linked transactions or other events. The Company determined that there were no embedded
derivatives to be identified, bifurcated and valued in connection with this financing.
The
2018 and 2019 Convertible Notes consist of the following at June 30, 2019 and December 31, 2018:
|
|
June 30, 2019
|
|
|
December 31, 2018
|
|
Principal amount of notes payable
|
|
$
|
190,000
|
|
|
$
|
80,000
|
|
Original issue discount net of amortization of $8,379
|
|
|
-
|
|
|
|
(27,968
|
)
|
Accrued interest payable
|
|
|
8,265
|
|
|
|
401
|
|
|
|
$
|
198,265
|
|
|
$
|
52,433
|
|
Convertible
notes were also sold to investors in 2014 and 2015 (“Original Convertible Notes), which aggregated a total of $579,500,
had a fixed interest rate of 10% per annum and those that remain outstanding are convertible into common stock at a fixed
price of $11.3750 per share. The Original Convertible Notes have no reset rights or other protections based on subsequent
equity transactions, equity-linked transactions or other events. The warrants to purchase 50,945 shares of common stock
issued in connection with the sale of the convertible notes were exercisable at a fixed price of $11.3750 per share. All such
warrants have either been exchanged as part of April and May 2016 note and warrant exchange agreements or expired on
September 15, 2016.
The
maturity date of the Original Convertible Notes was extended to September 15, 2016 and included the issuance of 27,936 additional
warrants to purchase common stock, exercisable at $11.375 per share of common stock, which expired on September 15, 2016.
The
remaining outstanding Original Convertible Notes (including those for which default notices have been received) consist of the
following at June 30, 2019 and December 31, 2018:
|
|
June 30, 2019
|
|
|
December 31, 2018
|
|
Principal amount of notes payable
|
|
$
|
125,000
|
|
|
$
|
125,000
|
|
Accrued interest payable
|
|
|
71,851
|
|
|
|
62,233
|
|
|
|
$
|
196,851
|
|
|
$
|
187,233
|
|
As
of June 30, 2019, principal and accrued interest on the one remaining outstanding Original Convertible Note, which is subject
to a default notice and which therefore accrues annual interest at 12% instead of 10%, totaled $40,957, of which $15,957
was accrued interest. As of December 31, 2018, principal and accrued interest on convertible notes subject to default notices
totaled $38,292 of which $13,292 was accrued interest.
As
of June 30, 2019, the remaining total outstanding Original Convertible Notes, inclusive of accrued interest, were convertible
into 17,256 shares of the Company’s common stock, including 6,321 shares attributable to accrued interest of $71,870 payable
as of such date. As of December 31, 2018, the outstanding Original Convertible Notes were convertible into 16,460 shares of the
Company’s common stock, including 5,471 shares attributable to accrued interest of $62,233 payable as of such date. Such
Original Convertible Notes will continue to accrue interest until exchanged, paid or otherwise discharged. There can be no assurance
that any of the additional holders of the remaining Original Convertible Notes will exchange their notes.
Note
Payable to SY Corporation Co., Ltd.
On
June 25, 2012, the Company borrowed 465,000,000 Won (the currency of South Korea, equivalent to approximately $400,000 United
States Dollars as of that date) from and executed a secured note payable to SY Corporation Co., Ltd., formerly known as
Samyang Optics Co. Ltd. (“SY Corporation”), an approximately 20% common stockholder of the Company at that time.
SY Corporation was a significant stockholder and a related party at the time of the transaction but has not been a
significant stockholder or related party of the Company subsequent to December 31, 2014. The note accrues simple interest at
the rate of 12% per annum and had a maturity date of June 25, 2013. The Company has not made any payments on the promissory
note. At June 30, 2013 and subsequently, the promissory note was outstanding and in default, although SY Corporation has not
issued a notice of default or a demand for repayment. Management believes that SY Corporation is in default of its
obligations under its January 2012 license agreement, as amended, with the Company, but the Company has not yet issued a
notice of default. The Company has in the past made several efforts towards a comprehensive resolution of the aforementioned
matters involving SY Corporation. During the six months ended June 30, 2019, there were no communications between the Company
and SY Corporation.
The
promissory note is secured by collateral that represents a lien on certain patents owned by the Company, including composition
of matter patents for certain of the Company’s high impact ampakine compounds and the low impact ampakine compounds CX2007
and CX2076, and other related compounds. The security interest does not extend to the Company’s patents for its ampakine
compounds CX1739 and CX1942, or to the patent for the use of ampakine compounds for the treatment of respiratory depression.
Note
payable to SY Corporation consists of the following at June 30, 2019 and December 31, 2018:
|
|
June 30, 2019
|
|
|
December 31, 2018
|
|
Principal amount of note payable
|
|
$
|
399,774
|
|
|
$
|
399,774
|
|
Accrued interest payable
|
|
|
339,097
|
|
|
|
315,307
|
|
Foreign currency transaction adjustment
|
|
|
3,006
|
|
|
|
29,360
|
|
|
|
$
|
741,876
|
|
|
$
|
744,441
|
|
Interest
expense with respect to this promissory note was $23,789 and $11,960 for the six months and three months ended June 30, 2019 and
for the six months and three months ended June 30, 2018, respectively.
Notes
Payable to Officers and Former Officers
For
the six months and three months ended June 30, 2019, $5,094 and $2,561 respectively was charged to interest expense with respect
to notes payable to Dr. Arnold S. Lippa, an officer of the Company. For the six months and three months ended June
30, 2018, $5,664 and $3,364 respectively was charged to interest expense with respect to notes payable to Dr. Arnold S. Lippa.
For
the six months and three months ended June 30, 2019, $7,645 and $3,843 respectively was charged to interest expense with respect
notes payable to to Dr.James S. Manuso, a former officer of the Company. For the six months and three months ended
June 30, 2018 $5,642 and $3,363 respectivley was charged to interest expense with respect to notes payable to Dr. James S. Manuso.
As
of September 30, 2018, Dr. James S. Manuso resigned as executive officer in all capacities and as a member of the Board of Directors
of the Company. All of the $7,645 of interest expense noted above for the six months ended June 30, 2019, was incurred while Dr.
Manuso was no longer an officer.
Other
Short-Term Notes Payable
Other
short-term notes payable at June 30, 2019 and December 31, 2018 consisted of premium financing agreements with respect to various
insurance policies. At the inception of the new policy in March 2019, a premium financing agreement was payable in the
initial amount of $61,746, with interest at 9% per annum, in nine monthly installments of $7,120. At June 30, 2019 and December
31, 2018, the aggregate amount of the short-term notes payable was $48,575 and $8,907 respectively.
5.
Settlement and Payment Agreements
There
were no settlement or payment agreements entered into during the three month or six month periods ended June 30,
2019 or 2018. In July, 2019, the Company and a vendor agreed in principle to a proposed settlement agreement. See Note
9. Subsequent Events.
6.
Stockholders’ Deficiency
Preferred
Stock
The
Company has authorized a total of 5,000,000 shares of preferred stock, par value $0.001 per share. As of June 30, 2019 and December
31, 2018, 1,250,000 shares were designated as 9% Cumulative Convertible Preferred Stock (non-voting, “9% Preferred Stock”);
37,500 shares were designated as Series B Convertible Preferred Stock (non-voting, “Series B Preferred Stock”); 205,000
shares were designated as Series A Junior Participating Preferred Stock (non-voting, “Series A Junior Participating Preferred
Stock”); and 1,700 shares were designated as Series G 1.5% Convertible Preferred Stock. Accordingly, as of June 30, 2019
and December 31, 2018, 3,505,800 shares of preferred stock were undesignated and may be issued with such rights and powers as
the Board of Directors may designate.
Series
B Preferred Stock outstanding as of June 30, 2019 and 2018 consisted of 37,500 shares issued in a May 1991 private placement.
Each share of Series B Preferred Stock is convertible into approximately 0.00030 shares of common stock at an effective conversion
price of $2,208.375 per share of common stock, which is subject to adjustment under certain circumstances. As of June 30, 2019
and December 31, 2018, the shares of Series B Preferred Stock outstanding are convertible into 11 shares of common stock. The
Company may redeem the Series B Preferred Stock for $25,001, equivalent to $0.6667 per share, an amount equal to its liquidation
preference, at any time upon 30 days prior notice.
Common
Stock
There
are 3,872,076 shares of the Company’s Common Stock outstanding as of June 30, 2019. The Company has reserved an aggregate
of 5,197,583 for conversions of convertible debt which reserve includes contractual reserves totaling 5,180,327 shares of the
Company’s Common Stock, which exceeds the actual conversion amounts under those contracts as of June 30, 2019 by 4,632,786
shares. In addition, The Company has reserved 6,209,961 shares of the Company’s Common Stock for exercises of common stock
purchase options granted and warrants issued. There are 6,497 shares of the Company’s Common Stock reserved as Pier contingent
shares. There are 4,490,578 shares reserved for future issuances under the Company’s 2014 and 2015 Plans (as hereafter defined).
There are 45,223,294 shares of the Company’s Common Stock available for future issuances.
Common
Stock Warrants
Information
with respect to the issuance and exercise of common stock purchase warrants in connection with the Convertible Note Payable and
the related warrant, and Notes Payable to Officers, is provided at Note 4.
A
summary of warrant activity for the six months ended June 30, 2019 is presented below.
|
|
|
|
|
|
|
|
Weighted
|
|
|
|
|
|
|
|
|
|
Average
|
|
|
|
|
|
|
Weighted
|
|
|
Remaining
|
|
|
|
Number of
|
|
|
Average
|
|
|
Contractual
|
|
|
|
Shares
|
|
|
Exercise Price
|
|
|
Life (in Years)
|
|
Warrants outstanding at December 31, 2018
|
|
|
1,783,229
|
|
|
$
|
2.20393
|
|
|
|
3.06
|
|
Issued
|
|
|
152,372
|
|
|
|
1.41101
|
|
|
|
|
|
Expired
|
|
|
(59,403
|
)
|
|
|
2.65928
|
|
|
|
|
|
Warrants outstanding at June 30, 2019
|
|
|
1,876,198
|
|
|
$
|
2.12512
|
|
|
|
2.79
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Warrants exercisable at June 30, 2019
|
|
|
1,876,198
|
|
|
$
|
2.12512
|
|
|
|
2.79
|
|
The
exercise prices of common stock warrants outstanding and exercisable are as follows at June 30, 2019:
Exercise Price
|
|
|
Warrants Outstanding
(Shares)
|
|
|
Warrants Exercisable
(Shares)
|
|
|
Expiration Date
|
$
|
1.0000
|
|
|
|
916,217
|
|
|
|
916,217
|
|
|
September 20, 2022
|
$
|
1.1800
|
|
|
|
42,372
|
|
|
|
42,372
|
|
|
May 17, 2022
|
$
|
1.5000
|
|
|
|
190,000
|
|
|
|
190,000
|
|
|
December 30, 2023
|
$
|
1.5620
|
|
|
|
130,284
|
|
|
|
130,284
|
|
|
December 31, 2021
|
$
|
1.5750
|
|
|
|
238,814
|
|
|
|
238,814
|
|
|
April 30, 2023
|
$
|
2.7500
|
|
|
|
8,000
|
|
|
|
8,000
|
|
|
September 20, 2022
|
$
|
4.8500
|
|
|
|
5,155
|
|
|
|
5,155
|
|
|
September 23, 2019
|
$
|
4.8750
|
|
|
|
108,594
|
|
|
|
108,594
|
|
|
September 30, 2020
|
$
|
5.0000
|
|
|
|
5,000
|
|
|
|
5,000
|
|
|
September 22, 2019
|
$
|
6.8348
|
|
|
|
145,758
|
|
|
|
145,758
|
|
|
September 30, 2020
|
$
|
7.9300
|
|
|
|
86,004
|
|
|
|
86,004
|
|
|
February 28, 2021
|
|
|
|
|
|
1,876,198
|
|
|
|
1,876,198
|
|
|
|
Based
on a fair market value of $0.70 per share on June 30, 2019, there was no intrinsic value of exercisable in-the-money common
stock warrants as of June 30, 2019.
A
summary of warrant activity for the six months ended June 30, 2018 is presented below.
|
|
Number of
Shares
|
|
|
Weighted
Average
Exercise Price
|
|
|
Weighted
Average
Remaining
Contractual
Life (in Years)
|
|
Warrants outstanding at December 31, 2017
|
|
|
1,464,415
|
|
|
$
|
2.68146
|
|
|
|
4.88
|
|
Issued
|
|
|
-
|
|
|
|
-
|
|
|
|
|
|
Warrants outstanding at June 30, 2018
|
|
|
1,464,415
|
|
|
$
|
2.68146
|
|
|
|
4.29
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Warrants exercisable at December 31, 2017
|
|
|
1,464,415
|
|
|
$
|
2,68146
|
|
|
|
4.88
|
|
Warrants exercisable at June 30, 2018
|
|
|
1,464,415
|
|
|
$
|
2.68146
|
|
|
|
4.29
|
|
The
exercise prices of common stock warrants outstanding and exercisable are as follows at June 30, 2018:
Exercise Price
|
|
|
Warrants Outstanding
(Shares)
|
|
|
Warrants Exercisable
(Shares)
|
|
|
Expiration Date
|
$
|
1.0000
|
|
|
|
916,217
|
|
|
|
916,217
|
|
|
September 20, 2022
|
$
|
1.2870
|
|
|
|
41,002
|
|
|
|
41,002
|
|
|
April 17, 2019
|
$
|
1.5620
|
|
|
|
130,284
|
|
|
|
130,284
|
|
|
December 31, 2021
|
$
|
2.7500
|
|
|
|
8,000
|
|
|
|
8000
|
|
|
September 20, 2022
|
$
|
4.8500
|
|
|
|
5,155
|
|
|
|
5,155
|
|
|
September 23, 2019
|
$
|
4.8750
|
|
|
|
108,594
|
|
|
|
108,594
|
|
|
September 30, 2020
|
$
|
5.0000
|
|
|
|
5,000
|
|
|
|
5,000
|
|
|
September 22, 2019
|
$
|
5.1025
|
|
|
|
10,309
|
|
|
|
10,309
|
|
|
January 29, 2019
|
$
|
6.5000
|
|
|
|
8,092
|
|
|
|
8,092
|
|
|
February 4, 2019
|
$
|
6.8348
|
|
|
|
145,758
|
|
|
|
145,758
|
|
|
September 30, 2020
|
$
|
7.9300
|
|
|
|
86,004
|
|
|
|
86,004
|
|
|
February 28, 2021
|
|
|
|
|
|
1,464,415
|
|
|
|
1,464,415
|
|
|
|
Based
on a fair market value of $1.00 per share on June 30, 2018, there were no exercisable in-the money common stock warrants as of
June 30, 2018.
Stock
Options
On
March 18, 2014, the stockholders of the Company holding a majority of the votes to be cast on the issue approved the adoption
of the Company’s 2014 Equity, Equity-Linked and Equity Derivative Incentive Plan (the “2014 Plan”), which had
been previously adopted by the Board of Directors of the Company, subject to stockholder approval. The Plan permits the grant
of options and restricted stock with respect to up to 325,025 shares of common stock, in addition to stock appreciation rights
and phantom stock, to directors, officers, employees, consultants and other service providers of the Company.
On
June 30, 2015, the Board of Directors adopted the 2015 Stock and Stock Option Plan (the “2015 Plan”). The 2015 Plan
initially provided for, among other things, the issuance of either or any combination of restricted shares of common stock and
non- qualified stock options to purchase up to 461,538 shares of the Company’s common stock for periods up to ten years
to management, members of the Board of Directors, consultants and advisors. The Company has not and does not intend to present
the 2015 Plan to stockholders for approval. On August 18, 2015, the Board of Directors increased the number of shares that may
be issued under the 2015 Plan to 769,231 shares of the Company’s common stock. On March 31, 2016, the Board of Directors
further increased the number of shares that may be issued under the 2015 Plan to 1,538,461 shares of the Company’s common
stock. On January 17, 2017, the Board of Directors further increased the number of shares that may be issued under the 2015 Plan
to 3,038,461 shares of the Company’s common stock. On December 9, 2017, the Board of Directors further increased the number
of shares that may be issued under the 2015 Plan to 6,985,260 shares of the Company’s common stock. On December 28, 2018,
the Board of Directors further increased the number of shares that may be issued under the 2015 Plan to 8,985,260 shares of the
Company’s common stock.
Information
with respect to the Black-Scholes variables used in connection with the evaluation of the fair value of stock- based compensation
is provided at Note 3.
There
were no grants of common stock options or of stock for the six month period ended June 30, 2019.
A
summary of stock option activity for the six months ended June 30, 2019 is presented below.
|
|
Number
of
Shares
|
|
|
Weighted
Average
Exercise
Price
|
|
|
Weighted
Average
Remaining
Contractual
Life (in Years)
|
|
Options outstanding at
December 31, 2018
|
|
|
4,344,994
|
|
|
$
|
3.7634
|
|
|
|
7.38
|
|
Expired
|
|
|
(11,231
|
)
|
|
|
(13.000)
|
|
|
|
|
|
Options outstanding at June 30, 2019
|
|
|
4,333,763
|
|
|
$
|
3.5169
|
|
|
|
5.43
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Options exercisable at December 31, 2018
|
|
|
3,996,167
|
|
|
$
|
3.7634
|
|
|
|
7.38
|
|
Options exercisable at June 30, 2019
|
|
|
4,333,763
|
|
|
$
|
3.5169
|
|
|
|
5.43
|
|
The
exercise prices of common stock options outstanding and exercisable were as follows at June 30, 2019:
Exercise Price
|
|
|
Options
Outstanding
(Shares)
|
|
|
Options
Exercisable
(Shares)
|
|
|
Expiration Date
|
$
|
0.7000
|
|
|
|
21,677
|
|
|
|
21,677
|
|
|
November 21, 2023
|
$
|
1.1200
|
|
|
|
310,388
|
|
|
|
310,388
|
|
|
April 5, 2023
|
$
|
1.2500
|
|
|
|
16,762
|
|
|
|
16,762
|
|
|
December 7, 2022
|
$
|
1.3500
|
|
|
|
34,000
|
|
|
|
34,000
|
|
|
July 28, 2022
|
$
|
1.4500
|
|
|
|
1,849,418
|
|
|
|
1,849,418
|
|
|
December 9, 2027
|
$
|
1.4500
|
|
|
|
100,000
|
|
|
|
100,000
|
|
|
December 9, 2027
|
$
|
2.0000
|
|
|
|
285,000
|
|
|
|
285,000
|
|
|
June 30, 2022
|
$
|
2.0000
|
|
|
|
25,000
|
|
|
|
25,000
|
|
|
July 26, 2022
|
$
|
3.9000
|
|
|
|
395,000
|
|
|
|
395,000
|
|
|
January 17, 2022
|
$
|
4.5000
|
|
|
|
7,222
|
|
|
|
7,222
|
|
|
September 2, 2021
|
$
|
5.6875
|
|
|
|
89,686
|
|
|
|
89,686
|
|
|
June 30, 2020
|
$
|
5.7500
|
|
|
|
2,608
|
|
|
|
2,608
|
|
|
September 12, 2021
|
$
|
6.4025
|
|
|
|
27,692
|
|
|
|
27,692
|
|
|
August 18, 2020
|
$
|
6.4025
|
|
|
|
129,231
|
|
|
|
129,231
|
|
|
August 18, 2022
|
$
|
6.4025
|
|
|
|
261,789
|
|
|
|
261,789
|
|
|
August 18, 2025
|
$
|
6.8250
|
|
|
|
8,791
|
|
|
|
8,791
|
|
|
December 11, 2020
|
$
|
7.3775
|
|
|
|
523,077
|
|
|
|
523,077
|
|
|
March 31, 2021
|
$
|
8.1250
|
|
|
|
169,231
|
|
|
|
169,231
|
|
|
June 30, 2022
|
$
|
13.9750
|
|
|
|
3,385
|
|
|
|
3,385
|
|
|
March 14, 2024
|
$
|
15.4700
|
|
|
|
7,755
|
|
|
|
7,755
|
|
|
April 8, 2020
|
$
|
15.9250
|
|
|
|
2,462
|
|
|
|
2,462
|
|
|
February 28, 2024
|
$
|
16.0500
|
|
|
|
46,154
|
|
|
|
46,154
|
|
|
July 17, 2019
|
$
|
16.6400
|
|
|
|
1,538
|
|
|
|
1,538
|
|
|
January 29, 2020
|
$
|
19.5000
|
|
|
|
9,487
|
|
|
|
9,487
|
|
|
July 17, 2022
|
$
|
19.5000
|
|
|
|
6,410
|
|
|
|
6,410
|
|
|
August 10, 2022
|
|
|
|
|
|
4,333,763
|
|
|
|
4,333,763
|
|
|
|
There
was no deferred compensation expense for the outstanding stock options at June 30, 2019.
Based
on a fair market value of $0.7000 per share on June 30, 2019, there was no intrinsic value of exercisable in-the-money common
stock options as of June 30, 2019.
A summary of stock
option activity for the six months ended June 30, 2018 is presented below.
|
|
Number
of
Shares
|
|
|
Weighted
Average
Exercise
Price
|
|
|
Weighted
Average
Remaining
Contractual
Life (in Years)
|
|
Options outstanding at
December 31, 2017
|
|
|
3,996,167
|
|
|
$
|
3.7634
|
|
|
|
7.38
|
|
Granted
|
|
|
327,150
|
|
|
|
1.1267
|
|
|
|
4.75
|
|
Options outstanding at June 30, 2018
|
|
|
4,323,317
|
|
|
$
|
3.5855
|
|
|
|
6.42
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Options exercisable at December 31, 2017
|
|
|
3,996,167
|
|
|
$
|
3.7634
|
|
|
|
7.38
|
|
Options exercisable at June 30, 2018
|
|
|
4,323,317
|
|
|
$
|
3.5855
|
|
|
|
6.42
|
|
The
exercise prices of common stock options outstanding and exercisable were as follows at June 30, 2018:
Exercise Price
|
|
|
Options Outstanding
(Shares)
|
|
|
Options Exercisable
(Shares)
|
|
|
Expiration Date
|
$
|
1.1200
|
|
|
|
310,388
|
|
|
|
310,388
|
|
|
April 5, 2023
|
$
|
1.2500
|
|
|
|
16,762
|
|
|
|
16,762
|
|
|
December 7, 2022
|
$
|
1.3500
|
|
|
|
34,000
|
|
|
|
34,000
|
|
|
July 28, 2022
|
$
|
1.4500
|
|
|
|
1,849,418
|
|
|
|
1,849,418
|
|
|
December 9, 2027
|
$
|
1.4500
|
|
|
|
100,000
|
|
|
|
100,000
|
|
|
December 9, 2027
|
$
|
2.0000
|
|
|
|
285,000
|
|
|
|
285,000
|
|
|
June 30, 2022
|
$
|
2.0000
|
|
|
|
25,000
|
|
|
|
25,000
|
|
|
July 26, 2022
|
$
|
3.9000
|
|
|
|
395,000
|
|
|
|
395,000
|
|
|
January 17, 2022
|
$
|
4.5000
|
|
|
|
7,222
|
|
|
|
7,222
|
|
|
September 2, 2021
|
$
|
5.6875
|
|
|
|
89,686
|
|
|
|
89,686
|
|
|
June 30, 2020
|
$
|
5.7500
|
|
|
|
2,608
|
|
|
|
2,608
|
|
|
September 12, 2021
|
$
|
6.4025
|
|
|
|
27,692
|
|
|
|
27,692
|
|
|
August 18, 2020
|
$
|
6.4025
|
|
|
|
129,231
|
|
|
|
129,231
|
|
|
August 18, 2022
|
$
|
6.4025
|
|
|
|
261,789
|
|
|
|
261,789
|
|
|
August 18, 2025
|
$
|
6.8250
|
|
|
|
8,791
|
|
|
|
8,791
|
|
|
December 11, 2020
|
$
|
7.3775
|
|
|
|
523,077
|
|
|
|
523,077
|
|
|
March 31, 2021
|
$
|
8.1250
|
|
|
|
169,231
|
|
|
|
169,231
|
|
|
June 30, 2022
|
$
|
13.0000
|
|
|
|
7,385
|
|
|
|
7,385
|
|
|
March 13, 2019
|
$
|
13.0000
|
|
|
|
3,846
|
|
|
|
3,846
|
|
|
April 14, 2019
|
$
|
13.9750
|
|
|
|
3,385
|
|
|
|
3,385
|
|
|
March 14, 2024
|
$
|
15.4700
|
|
|
|
7,755
|
|
|
|
7,755
|
|
|
April 8, 2020
|
$
|
15.9250
|
|
|
|
2,462
|
|
|
|
2,462
|
|
|
February 28, 2024
|
$
|
16.0500
|
|
|
|
46,154
|
|
|
|
46,154
|
|
|
July 17, 2019
|
$
|
16.6400
|
|
|
|
1,538
|
|
|
|
1,538
|
|
|
January 29, 2020
|
$
|
19.5000
|
|
|
|
9,487
|
|
|
|
9,487
|
|
|
July 17, 2022
|
$
|
19.5000
|
|
|
|
6,410
|
|
|
|
6,410
|
|
|
August 10, 2022
|
|
|
|
|
|
4,323,317
|
|
|
|
4,323,317
|
|
|
|
Based
on a fair market value of $1.00 per share on June 30, 2018, there were no exercisable in-the-money common stock options as of
June 30, 2018.
Reserved
and Unreserved Shares of Common Stock
On
January 17, 2017, the Board of Directors of the Company approved the adoption of an amendment of the Amended and Restated RespireRx
Pharmaceuticals, Inc. 2015 Stock and Stock Option Plan (as amended, the “2015 Plan”). That amendment increases the
shares issuable under the plan by 1,500,000, from 1,538,461 to 3,038,461. On December 9, 2017, the Board of Directors further
amended the 2015 Plan to increase the number of shares that may be issued under the 2015 Plan to 6,985,260 shares of the Company’s
common stock. On December 28, 2018, the Board of Directors further amended the 2015 Plan to increase the number of shares that
may be issued under the 2015 Plan to 8,985,260 shares of the Company’s common stock.
Other
than the change in the number of shares available under the 2015 Plan, no other changes were made to the 2015 Plan by these amendments
noted above.
At
June 30, 2019, the Company had 65,000,000 shares of common stock authorized and 3,872,076 shares of common stock issued and outstanding.
The Company has reserved an aggregate of 5,197,583 for conversions of convertible debt which reserve includes contractual reserves
totaling 5,180,327 shares of the Company’s Common Stock, which exceeds the actual conversion amounts under those contracts
as of June 30, 2019 by 4,632,786 shares. In addition, The Company has reserved 6,209,961 shares of the Company’s Common
Stock for exercises of common stock purchase options granted and warrants issued. There are 6,497 shares of the Company’s
Common Stock reserved as Pier contingent shares. There are 4,490,578 shares reserved for future issuances under the Company’s
2014 and 2015 Plans (as hereafter defined). Accordingly, after taking into consideration the reserved shares, there are 45,223,294
shares of the Company’s Common Stock available for future issuances. The Company expects to satisfy its future common stock
commitments through the issuance of authorized but unissued shares of common stock.
7.
Related Party Transactions
Dr.
Arnold S. Lippa and Jeff E. Margolis, officers and directors of the Company since March 22, 2013, have indirect ownership interests
and managing memberships in Aurora Capital LLC (“Aurora”) through interests held in its members, and Jeff. E. Margolis
is also an officer of Aurora. Aurora is a boutique investment banking firm specializing in the life sciences sector that is also
a full-service brokerage firm.
A
description of advances and notes payable to officers is provided at Note 4.
8.
Commitments and Contingencies
Pending
or Threatened Legal Action and Claims
By
letter dated May 18, 2018, the Company received notice from counsel claiming to represent TEC Edmonton and The Governors of
the University of Alberta, which purported to terminate, effective December 12, 2017, the license agreement dated May 9, 2007
between the Company and The Governors of the University of Alberta. The Company, through its counsel, disputed any grounds
for termination and notified the representative that it invoked Section 13 of that license agreement, which mandates a
meeting to be attended by individuals with decision-making authority to attempt in good faith to negotiate a resolution to
the dispute. In February 2019, the Company and TEC Edmonton tentatively agreed to terms acceptable to all parties to
establish a new license agreement and the form of a new license agreement. However, the parties have not signed the draft new
license agreement pending the
Company’s payment of the agreed amount of historical unreimbursed patent fees of
approximately CAD$23,000 (approximately US$17,000 as of June 30, 2019). No assurance can be provided that the Company will or
will not be able to remit the historical license fees or that the draft new license agreement will be executed and become
effective. If we do not remit the historical fees and the new license agreement does not become effective, we cannot estimate
the possible adverse impact on the Company’s operations or business prospects.
By
e-mail dated July 21, 2016, the Company received a demand from an investment banking consulting firm that represented the Company
in 2012 in conjunction with the Pier transaction alleging that $225,000 is due and payable for investment banking services rendered.
Such amount has been included in accrued expenses at June 30, 2019 and December 31, 2018.
By
letter dated February 5, 2016, the Company received a demand from a law firm representing a professional services vendor of the
Company alleging an amount due and payable for services rendered. On January 18, 2017, following an arbitration proceeding, an
arbitrator awarded the vendor the full amount sought in arbitration of $146,082. Additionally, the arbitrator granted the vendor
attorneys’ fees and costs of $47,937. All such amounts have been included in accrued expenses at June 30, 2019 and December
31, 2018, including accrued interest at 4.5% annually from February 26, 2018, the date of the judgment, through June 30, 2019,
totaling $11,859 and which amounts at December 31, 2018 totaled $7,470. In July 2019 the Company and this vendor agreed in
principle to a proposed settlement agreement. See Note 9. Subsequent Events.
The
Company is periodically the subject of various pending and threatened legal actions and claims. In the opinion of management of
the Company, adequate provision has been made in the Company’s consolidated financial statements as of June 30, 2019 and
December 31, 2018 with respect to such matters, including, specifically, the matters noted above. The Company intends to vigorously
defend itself if any of the matters described above results in the filing of a lawsuit or formal claim.
Significant
Agreements and Contracts
Consulting
Agreement
Richard
Purcell, the Company’s Senior Vice President of Research and Development since October 15, 2014, provides his services to
the Company on a month-to-month basis through his consulting firm, DNA Healthlink, Inc., through which the Company has contracted
for his services, for a monthly cash fee of $12,500. Additional information with respect to shares of common stock that have been
issued to Mr. Purcell is provided at Note 6. Cash compensation expense pursuant to this agreement totaled $75,000 and $37,500
for the six months and three months ended June 30, 2019 and 2018, which is included in research and development expenses in the
Company’s consolidated statements of operations for such periods.
Employment
Agreements
On
October 12, 2018, Dr. Lippa was named Interim President and Interim Chief Executive Officer to replace Dr. Manuso who
resigned effective September 30, 2018. Dr. Lippa continues to serve as the Company’s Executive Chairman and as a member
of the Board of Directors. Also, on August 18, 2015, Dr. Lippa was named Chief Scientific Officer of the Company, and the
Company entered into an employment agreement with Dr. Lippa in that capacity. Pursuant to the agreement, which is for an
initial term through September 30, 2018 (and which automatically extended on September 30, 2018 and will automatically extend
annually, upon the same terms and conditions, for successive periods of one year, unless either party provides written notice
of its intention not to extend the term of the agreement at least 90 days prior to the applicable renewal date), Dr. Lippa
received an annual base salary of $300,000. Dr. Lippa is also eligible to earn a performance-based annual bonus award of up
to 50% of his base salary, based upon the achievement of annual performance goals established by the Board of Directors in
consultation with the executive prior to the start of such fiscal year, or any amount at the discretion of the Board of
Directors. Additionally, Dr. Lippa was granted stock options to acquire 30,769 shares of common stock of the Company and is
eligible to receive additional awards under the Company’s Plans at the discretion of the Board of Directors. Dr. Lippa
is also entitled to receive, until such time as the Company establishes a group health plan for its employees,
$1,200
per month, on a tax-equalized basis, as additional compensation to cover the cost of health coverage and up to $1,000 per
month, on a tax-equalized basis, as reimbursement for a term life insurance policy and disability insurance policy. Dr. Lippa
is also entitled to be reimbursed for business expenses. Additional information with respect to the stock options granted to
Dr. Lippa is provided at Note 6. Cash compensation accrued pursuant to this agreement totaled $169,800 and $84,900 for the
six months and three months ended June 30, 2019 and 2018, respectively, which amounts are included in accrued compensation
and related expenses in the Company’s consolidated balance sheet at June 30, 2019 and December 31, 2018, and in
research and development expenses in the Company’s consolidated statement of operations. Dr. Lippa does not receive any
additional compensation for serving as Executive Chairman and on the Board of Directors.
On
August 18, 2015, the Company also entered into an employment agreement with Jeff E. Margolis, in his continuing role as Vice President,
Secretary and Treasurer. Pursuant to the agreement, which was for an initial term through September 30, 2016 (and which automatically
extended on September 30, 2016 and will automatically extend annually upon the same terms and conditions, for successive periods
of one year, unless either party provides written notice of its intention not to extend the term of the agreement at least 90
days prior to the applicable renewal date), Mr. Margolis received an annual base salary of $195,000, and is also eligible to receive
performance-based annual bonus awards ranging from $65,000 to $125,000, based upon the achievement of annual performance goals
established by the Board of Directors in consultation with the executive prior to the start of such fiscal year, or any amount
at the discretion of the Board of Directors. Additionally, Mr. Margolis was granted stock options to acquire 30,769 shares of
common stock of the Company and is eligible to receive additional awards under the Company’s Plans at the discretion of
the Board of Directors. Mr. Margolis is also entitled to receive, until such time as the Company establishes a group health plan
for its employees, $1,200 per month, on a tax-equalized basis, as additional compensation to cover the cost of health coverage
and up to $1,000 per month, on a tax-equalized basis, as reimbursement for a term life insurance policy and disability insurance
policy. Mr. Margolis is also entitled to be reimbursed for business expenses. Additional information with respect to the stock
options granted to Mr. Margolis is provided at Note 6. Mr. Margolis’ employment agreement was amended effective July 1,
2017. The employment agreement amendment called for payment in three installments in cash of the $60,000 bonus granted on June
30, 2015. A minimum of $15,000 was to be payable in cash as follows: (a) $15,000 payable in cash upon the next closing (after
July 1, 2017) of any financing in excess of $100,000 (b) $15,000 payable by the end of the following month assuming cumulative
closings (beginning with the closing that triggered (a)) in excess of $200,000 and (c) $30,000 payable in cash upon the next closing
of any financing in excess of an additional $250,000. The conditions of (a), (b) and (c) above were met as of December 31, 2017,
however Mr. Margolis has waived the Company’s obligation to make any payments of the cash bonus until the Board of Directors
of the Company determines that sufficient capital has been raised by the Company or is otherwise available to fund the Company’s
operations on an ongoing basis. Recurring cash compensation accrued pursuant to this amended agreement totaled $160,800 and $80,400
for the six months and three months ended June 30, 2019 and 2018 and were $321,600 for the fiscal year ended December 31, 2018.
Such amounts are included in accrued compensation and related expenses in the Company’s consolidated balance sheet at June
30, 2019 and December 31, 2018 respectively, and in general and administrative expenses in the Company’s consolidated statement
of operations.
The
employment agreements between the Company and each of Dr. Lippa and Mr. Margolis (prior to the 2017 amendment), respectively,
provided that the payment obligations associated with the first year base salary were to accrue, but no payments were to be made,
until at least $2,000,000 of net proceeds from any offering or financing of debt or equity, or a combination thereof, was received
by the Company, at which time scheduled payments were to commence. Dr. Lippa and Mr. Margolis (who are each also directors of
the Company), and prior to his resignation, Dr. James S. Manuso, have each agreed, effective as of August 11, 2016, to continue
to defer the payment of such amounts indefinitely, until such time as the Board of Directors of the Company determines that sufficient
capital has been raised by the Company or is otherwise available to fund the Company’s operations on an ongoing basis.
University
of Alberta License Agreement
On
May 9, 2007, the Company entered into a license agreement, as amended, with the University of Alberta granting the Company exclusive
rights to practice patents held by the University of Alberta claiming the use of ampakines for the treatment of various respiratory
disorders. The Company agreed to pay the University of Alberta a licensing fee and a patent issuance fee, which were paid, and
prospective payments consisting of a royalty on net sales, sublicense fee payments, maintenance payments and milestone payments.
The prospective maintenance payments commence on the enrollment of the first patient into the first Phase 2B clinical trial and
increase upon the successful completion of the Phase 2B clinical trial. As the Company does not at this time anticipate scheduling
a Phase 2B clinical trial in the near term, no maintenance payments to the University of Alberta are currently due and payable,
nor are any maintenance payments expected to be due in the near future in connection with the license agreement. On May 18, 2018,
the Company received a letter from counsel claiming to represent TEC Edmonton and The Governors of the University of Alberta,
which purported to terminate, effective December 12, 2017, the license agreement dated May 9, 2007 (as subsequently amended) between
the Company and The Governors of the University of Alberta. The Company, through its counsel, disputed any grounds for termination
and notified the representative that it invoked Section 13 of that license agreement, which mandates a meeting to be attended
by individuals with decision-making authority to attempt in good faith to negotiate a resolution to the dispute. In February 2019,
the Company and TEC Edmonton tentatively agreed to terms acceptable to all parties to establish a new license agreement and the
form of a new license agreement. However, the parties have not signed the draft new license agreement pending the Company’s
payment of the agreed amount of historical unreimbursed patent fees, of approximately CAD$23,000 (approximately US$17,000 as of
June 30, 2019). No assurance can be provided that the Company will or will not be able to remit the historical license fees or
that the draft new license agreement will be executed and become effective. If we do not remit the historical fees and the new
license agreement does not become effective, we cannot estimate the possible adverse impact on the Company’s operations
or business prospects.
University
of Illinois 2014 Exclusive License Agreement
On
June 27, 2014, the Company entered into an Exclusive License Agreement (the “2014 License Agreement”) with the University
of Illinois, the material terms of which were similar to a License Agreement between the parties that had been previously terminated
on March 21, 2013. The 2014 License Agreement became effective on September 18, 2014, upon the completion of certain conditions
set forth in the 2014 License Agreement, including: (i) the payment by the Company of a $25,000 licensing fee, (ii) the payment
by the Company of outstanding patent costs aggregating $15,840, and (iii) the assignment to the University of Illinois of rights
the Company held in certain patent applications, all of which conditions were fulfilled.
The
2014 License Agreement granted the Company (i) exclusive rights to several issued and pending patents in numerous jurisdictions
and (ii) the non-exclusive right to certain technical information that is generated by the University of Illinois in connection
with certain clinical trials as specified in the 2014 License Agreement, all of which relate to the use of cannabinoids for the
treatment of sleep related breathing disorders. The Company is developing dronabinol (Δ9-tetrahydrocannabinol), a cannabinoid,
for the treatment of OSA, the most common form of sleep apnea.
The
2014 License Agreement provides for various commercialization and reporting requirements commencing on June 30, 2015. In addition,
the 2014 License Agreement provides for various royalty payments, including a royalty on net sales of 4%, payment on sub-licensee
revenues of 12.5%, and a minimum annual royalty beginning in 2015 of $100,000, which is due and payable on December 31 of each
year beginning on December 31, 2015. The minimum annual royalty obligation of $100,000 due on December 31, 2018, was extended
to February 28, 2019, when such payment obligation was paid by the Company. The minimum annual royalty obligation was paid as
scheduled in December 2017. One-time milestone payments may become due based upon the achievement of certain development milestones.
$350,000 will be due within five days after the dosing of the first patient is a Phase III human clinical trial anywhere in the
world. $500,000 will be due within five days after the first NDA filing with FDA or a foreign equivalent. $1,000,000 will be due
within twelve months of the first commercial sale. One-time royalty payments may also become due and payable. Annual royalty payments
may also become due. In the year after the first application for market approval is submitted to the FDA or a foreign equivalent
and until approval is obtained, the minimum annual royalty will increase to $150,000. In the year after the first market approval
is obtained from the FDA or a foreign equivalent and until the first sale of a product, the minimum annual royalty will increase
to $200,000. In the year after the first commercial sale of a product, the minimum annual royalty will increase to $250,000. For
each of the six month and three month periods ending June 30, 2019 and 2018, the Company recorded a charge to operations of $50,000
and $25,000 with respect to its minimum annual royalty obligation, which is included in research and development expenses in the
Company’s consolidated statements of operations for the three-months ended June 30, 2019 and 2018.
As
of December 31, 2018, the Company received an extension of time to make a $100,000 payment that would have due on such date. An
additional extension was granted until February 28, 2019, on which date the Company made the required payment.
Research
Contract with the University of Alberta
On
January 12, 2016, the Company entered into a Research Contract with the University of Alberta in order to test the efficacy of
ampakines at a variety of dosage and formulation levels in the potential treatment of Pompe Disease, apnea of prematurity and
spinal cord injury, as well as to conduct certain electrophysiological studies to explore the ampakine mechanism of action for
central respiratory depression. The Company agreed to pay the University of Alberta total consideration of approximately CAD$146,000
(approximately US$111,000), consisting of approximately CAD$85,000 (approximately US$65,000) of personnel funding in cash in four
installments during 2016, to provide approximately CAD$21,000 (approximately US$16,000) in equipment, to pay patent costs of CAD$20,000
(approximately US$15,000), and to underwrite additional budgeted costs of CAD$20,000 (approximately US$15,000). The final amount
payable in respect to this Research Contract of US$16,207 (CAD$21,222) was paid in US dollars in January 2018 and completed the
payments under the contract. The conversion to US dollars above utilizes an exchange rate of approximately US$0.76 for every CAD$1.00.
The
University of Alberta received matching funds through a grant from the Canadian Institutes of Health Research in support of this
research. The Company retained the rights to research results and any patentable intellectual property generated by the research.
Dr. John Greer, faculty member of the Department of Physiology, Perinatal Research Centre and Women & Children’s Health
Research Institute at the University of Alberta collaborated on this research. The studies were completed in 2016.
See
“University of Alberta License Agreement” above for more information on the related license agreement.
Summary
of Principal Cash Obligations and Commitments
The
following table sets forth the Company’s principal cash obligations and commitments for the next five fiscal years as of
June 30, 2019, aggregating $740,300 License agreement amounts included in the 2019 column represents amounts contractually due
from July 1, 2019 through December 31, 2019 (six months) and in each of the subsequent years, represents the full year. Employment
agreement amounts included in the 2019 column represent amounts contractually due at from July 1, 2019 through September 30, 2019
(three months) when such contracts expire unless extended pursuant to the terms of the contracts.
|
|
|
|
|
|
|
Payments
Due By Year
|
|
|
|
|
Total
|
|
|
|
2019
|
|
|
|
2020
|
|
|
|
2021
|
|
|
|
2022
|
|
|
|
2023
|
|
License
agreements
|
|
$
|
450,000
|
|
|
$
|
50,000
|
|
|
$
|
100,000
|
|
|
$
|
100,000
|
|
|
$
|
100,000
|
|
|
$
|
100,000
|
|
Litigation
settlement
|
|
|
125,000
|
|
|
$
|
125,000
|
|
|
|
-
|
|
|
|
-
|
|
|
|
-
|
|
|
|
-
|
|
Employment
agreements (1)
|
|
|
165,300
|
|
|
|
165,300
|
|
|
|
-
|
|
|
|
-
|
|
|
|
-
|
|
|
|
-
|
|
Total
|
|
$
|
740,300
|
|
|
$
|
340,300
|
|
|
$
|
100,000
|
|
|
$
|
100,000
|
|
|
$
|
100,000
|
|
|
$
|
100,000
|
|
(1)
The payment of such amounts has been deferred indefinitely, as described above at “Employment Agreements.” The 2019
amounts include three months of employment agreement obligations for Dr. Lippa and Mr. Margolis as their employment contracts
renewed on September 30, 2018 and the 2019 obligations include the three months of obligations through September 30, 2019.
9.
Subsequent Events
On
July 29, 2019, the Company reached an agreement in principle with Salamandra, LLC (“Salamandra”) in
respect to amounts owed to Salamandra and on the same date, the Company delivered to Salamandra its signature to the proposed
settlement agreement. As of August 9, 2019, the Company had not as yet received Salamandra’s signature to the
proposed settlement agreement. As of June 30, 2019, the Company had recorded amounts owed of $202,395 after payments on June 11,
2019 of remittances totaling $3,483. The settlement agreement calls for, among other things, a reduction in the amount owed to
$125,000, payable by November 30, 2019 in one-lump sum, once the Company has raised an aggregate of at least $600,000. Should
the Company raise less than $600,000, the Company may pay 21% of the amount raised and cancel that portion of the debt. If the
Company is unable to raise $600,000 by November 30, 2019, the settlement agreement becomes null and void. Upon receipt of the
settlement payment, mutual releases will become effective with respect to the remaining amount of debt on that date.